{{Drugbox
| verifiedrevid = 460792611
| IUPAC_name = 4-benzhydryloxy-1-methyl-piperidine
| image = Diphenylpyraline.svg
| width = 180

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|diphenylpyraline}}
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = [[Mouth|Oral]], [[Topical]]

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life = 24–40 hours<ref name="pmid4156058">{{cite journal | vauthors = Graham G, Bolt AG | title = Half-life of diphenylpyraline in man | journal = Journal of Pharmacokinetics and Biopharmaceutics | volume = 2 | issue = 3 | pages = 191–5 |date=June 1974 | pmid = 4156058 | doi = 10.1007/BF01059761 | url = }}</ref>
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 7165
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 147-20-6
| ATC_prefix = R06
| ATC_suffix = AA07
| PubChem = 3103
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01146
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2992
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 33361OE3AV
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07862
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 59788
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1492

<!--Chemical data-->
| C=19 | H=23 | N=1 | O=1
| molecular_weight = 281.392 g/mol
| smiles = O(C(c1ccccc1)c2ccccc2)C3CCN(C)CC3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OWQUZNMMYNAXSL-UHFFFAOYSA-N
| synonyms = 4-(diphenylmethoxy)-1-methyl-piperidine
}}

'''Diphenylpyraline''' ('''DPP'''; sold as '''Allergen''', '''Arbid''', '''Belfene''', '''Diafen''', '''Hispril''', '''Histyn''', '''Lergobine''', '''Lyssipol''', '''Mepiben''', '''Neargal''') is a [[first-generation antihistamine]] with [[anticholinergic]] effects of the [[benzhydryl|diphenyl]][[piperidine]] class.<ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | pages = | isbn = 3-88763-075-0 | oclc = | doi = | url = https://books.google.com/books?id=5GpcTQD_L2oC&lpg=PA358&dq=Diphenylpyraline&pg=PA358#v=onepage&q}}</ref><ref name="pmid14039">{{cite journal | vauthors = Puhakka H, Rantanen T, Virolainen E | title = Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis | journal = J Int Med Res | volume = 5 | issue = 1 | pages = 37–41 | year = 1977 | pmid = 14039}}</ref><ref name="pmid2884340">{{cite journal | vauthors = Kubo N, Shirakawa O, Kuno T, Tanaka C | title = Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay | journal = Japanese Journal of Pharmacology | volume = 43 | issue = 3 | pages = 277–82 |date=March 1987 | pmid = 2884340 | doi = 10.1254/jjp.43.277| url = }}</ref> It is marketed in [[Europe]] for the treatment of [[allergy|allergies]].<ref name="isbn3-88763-075-0" /><ref name="pmid14039" /><ref name="isbn0-444-52166-6">{{cite book | author = Hruby, Victor J. | author2 = Ruben Vardanyan | author3 = Vardanyan, ۊRuben | title = Synthesis of essential drugs | publisher = Elsevier | location = Amsterdam | year = 2006 | pages = | isbn = 0-444-52166-6 | oclc = | doi = | url = https://books.google.com/books?id=Jjc7KYWZdOYC&lpg=PA230&dq=Diphenylpyraline&pg=PA230#v=onepage&q}}</ref> DPP has also been found to act as a [[dopamine reuptake inhibitor]] and produces [[hyperactivity]] in rodents.<ref name="pmid15627433">{{cite journal | vauthors = Lapa G, Mathews T, Harp J, Budygin E, Jones S | title = Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties | journal = Eur J Pharmacol | volume = 506 | issue = 3 | pages = 237–40 | year = 2005 | pmid = 15627433 | doi = 10.1016/j.ejphar.2004.11.017}}</ref> It has been shown to be useful in the treatment of [[Parkinsonism]].<ref name="pmid11137513">{{cite journal | vauthors = Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I | title = Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients | journal = J Neurol Sci | volume = 182 | issue = 2 | pages = 95–7 | year = 2001 | pmid = 11137513 | doi = 10.1016/S0022-510X(00)00441-X}}</ref>

==Synthesis==
[[File:Diphenylpyraline-synthesis.svg|500px|center|thumb|Diphenylpyraline synthesis via coupling of 4-hydroxy-1-methylpiperidine with benzhydrylbromide<ref>H.K. Lawrence, R. Kapp, {{US Patent|2479843}} (1949).</ref><ref>W.A. Schuler, {{Cite patent|DE|934890}} (1951).</ref>]]

== References ==
{{Reflist}}

{{Antihistamines}}
{{Antiparkinsonian}}
{{Stimulants}}
{{Acetylcholine receptor modulators}}
{{Dopamine receptor modulators}}
{{Monoamine reuptake inhibitors}}

[[Category:H1 receptor antagonists]]
[[Category:Piperidines]]
[[Category:Ethers]]
[[Category:Stimulants]]
[[Category:Phenyl compounds]]


{{Respiratory-system-drug-stub}}